Long non-coding rna in cancer

Abstract

There are provided polynucleotides that is able to bind to and inhibit the long non coding RNA transcript SCAT7. These polynucleotides can be used for the treatment of cancer. Expression analysis of SCAT7 can be used for diagnosis of cancer.

1 .- 12 . (canceled) 
     
     
         13 . A method for treatment of a disease comprising administering to a patient a polynucleotide that is able to bind to and inhibit a long non-coding RNA transcript that comprises or consists of the sequence SEQ ID NO 1 or SEQ ID NO 2, or a sequence that has at least 95% sequence identity to SEQ ID NO 1 or SEQ ID NO 2. 
     
     
         14 .- 19 . (canceled) 
     
     
         20 . The method of treatment of  claim 13 , wherein the disease is cancer. 
     
     
         21 . The method of treatment of  claim 13 , wherein the disease is selected from lung cancer, liver cancer, kidney cancer, bladder cancer, breast cancer, prostate cancer and endometrial cancer. 
     
     
         22 . The method of treatment of  claim 13 , wherein the disease is cancer which is resistant to chemotherapy. 
     
     
         23 . The method of  claim 13 , wherein the polynucleotide comprises or consists of a sequence selected from the group consisting of: SEQ ID NO 4, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, and SEQ ID NO 13. 
     
     
         24 . The method of  claim 13 , wherein the polynucleotide is a DNA antisense polynucleotide selected from SEQ ID NO 4 and SEQ ID NO 5, a shRNA polynucleotide selected from SEQ ID NO 6 and SEQ ID NO 7, or a siRNA polynucleotide which is a duplex of SEQ ID NO 8 and SEQ ID NO 9, a duplex of SEQ ID NO 10 and SEQ ID NO 11 or a duplex of SEQ ID NO 12 and SEQ ID NO 13. 
     
     
         25 . The method of  claim 13  wherein the disease is cancer and the cancer is resistant to an agent selected from the group consisting of actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bleomycin, bortezomib, capecitabine, cisplatin, carboplatin, chlorambucil cyclophosphamide, cytarabine, daunorubicin, dicycloplatin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, lipoplatin, mechlorethamine, mercaptopurine, methotrexate, mitoxantrone, nedaplatin, oxaliplatin, paclitaxel, pemetrexed, picoplatin, satraplatin, teniposide, tioguanine, topotecan, valrubicin, vemurafenib, vinblastine, vincristine, vindesine and vinorelbine. 
     
     
         26 . The method of  claim 13 , wherein the disease is cancer and the cancer is resistant to an platinum-based or platinum-containing chemotherapeutic agent. 
     
     
         27 . The method of  claim 13 , wherein the disease is cancer and the cancer is resistant to an agent selected from the group consisting of: cisplatin, carboplatin, dicycloplatin, lipoplatin, nedaplatin, oxaliplatin, picoplatin, and satraplatin. 
     
     
         28 . The method of  claim 13 , wherein the disease is cancer and the cancer is resistant to cisplatin.